Characteristics of maturity onset diabetes of the young in a large diabetes center

Pediatric Diabetes

Volumn 17, Issue 5, 2016, Pages 360-367

  Chambers, Christina ^a   Fouts, Alexandra ^a   Dong, Fran ^a   Colclough, Kevin ^b   Wang, Zhenyuan ^c   Batish, Sat Dev ^c   Jaremko, Malgorzata ^c   Ellard, Sian ^b   Hattersley, Andrew T ^b   Klingensmith, Georgeanna ^a   Steck, Andrea K ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c ATHENA DIAGNOSTICS INC   (United States)

Author keywords

GCK; HNF1A; HNF4A; MODY

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOKINASE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; PANCREATIC DUODENAL HOMEOBOX 1; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIABETOGENESIS; DISEASE DURATION; DNA SEQUENCE; FEMALE; GCK GENE; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CENTER; HNF1A GENE; HNF1B GENE; HNF4A GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATHOGENESIS; PDX1 GENE; PRIORITY JOURNAL;

EID: 84977581493     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12289     Document Type: Article

References (35)

1. Rubio-Cabezas O, Hattersley AT, Njølstad PR et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2014: 15 (S20): 47–64.
2. Ellard S, Bellanné-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008: 51: 546–553.
3. Steele AM, Wensley KJ, Ellard S et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One 2013: 8: e65326.
4. Kyithar MP, Bacon S, Pannu KK et al. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications. Diabetes Metab 2011: 37: 512–519.
5. Steck AK, Winter WE. Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes 2011: 18: 252–258.
6. Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet 2006: 43: 84–90.
7. Bellanné-Chantelot C, Chauveau D, Gautier J-F et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004: 140: 510–517.
8. Gandica RG, Chung WK, Deng L, Goland R, Gallagher MP. Identifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes. Pediatr Diabetes 2014: 16: 227–233.
9. Pihoker C, Gilliam LK, Ellard S et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab 2013: 98: 4055–4062.
10. Naylor RN, John PM, Winn AN et al. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care 2014: 37: 202–209.
11. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000: 17: 543–545.
12. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003: 362: 1275–1281.
13. Pearson ER, Pruhova S, Tack CJ et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection. Diabetologia 2005: 48: 878–885.
14. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009: 26: 437–441.
15. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1 alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003: 26: 3191–3192.
16. Ajjan RA, Owen KR. Glucokinase MODY and implications for treatment goals of common forms of diabetes. Curr Diab Rep 2014: 14: 559.
17. Spyer G, Macleod KM, Shepherd M, Ellard S, Hattersley AT. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 2009: 26: 14–18.
18. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM et al. CDC growth charts: United States. Adv Data 2000: 314: 1–27.
19. Yu L, Rewers M, Gianani R et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996: 81: 4264–4267.
20. Wallis Y, Payne S, McAnulty C, et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molegular Genetics [Internet]. [cited 2015 Apr 4] (available from http://www.acgs.uk.com/media/774853/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf).
21. Dunnen den JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000: 15: 7–12.
22. Andersson C, Vaziri-Sani F, Delli AJ et al. Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes 2012: 14: 97–105.
23. Yu L, Boulware DC, Beam CA et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012: 35: 1213–1218.
24. Pettitt DJ, Talton J, Dabelea D et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care 2014: 37: 402–408.
25. Ehtisham S. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 2004: 89: 526–529.
26. Lorini R, Klersy C, d'Annunzio G et al. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009: 32: 1864–1866.
27. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 1998: 15: 15–24.
28. Thanabalasingham G, Pal A, Selwood MP et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012: 35: 1206–1212.
29. Shepherd M, Hattersley AT. 'I don‘t feel like a diabetic any more’: the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Clin Med 2004: 4: 144–147.
30. Stanik J, Dusatkova P, Cinek O et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 2013: 57: 480–484.
31. Dabelea D, Rewers A, Stafford JM et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatr 2014: 133: e938–e945.
32. Pruhova S, Dusatkova P, Neumann D et al. Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY? Diabetes Care 2013: 36: 2573–2574.
33. Berger B, Stenström G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000: 60: 687–693.
34. Ludvigsson J, Carlsson A, Forsander G et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012: 13: 45–50.
35. Redondo MJ, Rodriguez LM, Escalante M, Smith EO, Balasubramanyam A, Haymond MW. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatr Diabetes 2013: 14: 333–340.